Deutsche downgrades GSK to Hold on Trump’s RFK nomination
Deutsche Bank downgraded GSK (GSK) to Hold from Buy with a price target of 1,350 GBp, down from 1,700 GBp. The firm cites President-elect ...
clinicaltrialsarena3h
GSK reports positive outcomes from Phase III multiple myeloma treatment trial
GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
TipRanks on MSN5h
GSK downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis downgraded GSK (GSK) to Hold from Buy with a price target of 1,350 GBp, down from 1,700 GBp. Published ...
STAT23h
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...